The Hidden Bottleneck in Every Tech Transfer: People

The post-mortem attributes it to "resource constraints" or "capacity gaps in the receiving team." Which is a polite way of saying: the right people were not in place when the transfer needed them.

That is the hidden bottleneck. Not the science. The people.

Tech transfers have a documented technical failure rate that is lower than most organisations assume. Processes designed to transfer generally do transfer eventually. What erodes timelines is rarely a fundamental process incompatibility. It is the slow accumulation of delays caused by human factors that sit outside the scope of the transfer protocol itself.

The most underacknowledged of these is what might be called the transparency gap.

When a sending site or development team prepares for a transfer, the formal package process description, batch records, analytical methods, comparability criteria is typically complete. What does not travel in that package is everything that exists in the minds of the people who developed and ran the process: the edge cases, the batch anomalies that were resolved informally, the parameters that are documented as ranges but are practically run tighter, the equipment sensitivities that were discovered through experience rather than design.

This tacit knowledge does not transfer automatically. And it transfers incompletely when the receiving team does not have the credibility to ask for it.

Experienced sending organisations make an intuitive assessment of the receiving team very early in a transfer. If that team is perceived as technically strong if the MSAT leads and process engineers on the receiving side clearly understand the modality, have navigated complex transfers before, and can engage as peers the transfer of informal knowledge flows more readily. Questions get answered fully. Assumptions get surfaced. The process as it was actually run, not just as it was documented, becomes accessible.

When the receiving team lacks that credibility, the transparency gap widens. Not through any deliberate withholding, but because the sending team has no confidence the receiving team will know what to do with what they share. The result is a transfer that is technically compliant but operationally incomplete.

This dynamic is increasingly consequential because the transfers happening right now are structurally more demanding than those that preceded them.

The European biopharma manufacturing investment cycle with over €3 billion in active CAPEX committed across the Netherlands, Belgium, Switzerland, and Ireland is not predominantly simple small-molecule work. The expansions driving the Genmab/Merus integration in Utrecht, the Sanofi buildout in Geel, and the Regeneron facility in Limerick involve biologics, peptide APIs, and in several cases, modalities with minimal transfer precedent in commercial manufacturing.

Each of these modalities introduces transfer-specific complexity. A biologics MSAT specialist cannot be assumed to bring directly applicable experience to a peptide API transfer. Cell therapy processes carry comparability challenges that standard biologics transfer frameworks do not address. ADC manufacturing introduces a dual-modality problem: the linker-payload chemistry, the antibody process, and the conjugation step each carry their own transfer risks and require MSAT capability across multiple technical domains simultaneously.

The pool of MSAT professionals who hold genuine cross-modality experience with complex biologics, ADCs, or peptides is small. It is being drawn upon simultaneously by multiple major European expansions on overlapping timelines. And the professionals who carry that experience who have navigated multi-site transfers in international regulatory contexts, who know what questions to ask and what documents to distrust are typically already engaged or committed well before formal searches begin.

The source documents supporting this analysis are direct about the downstream consequences of MSAT and process transfer capacity gaps. The figure most relevant to tech transfer specifically is this: the typical delay attributable to MSAT and validation capacity gaps in facility expansion projects is four to six months.

That figure is not a worst-case estimate. It is a recurring outcome across programmes that were otherwise well-planned.

The Genmab/Merus integration in Utrecht a €120M+ expansion supporting what became part of an $8 billion acquisition illustrates the stakes. When a biologics transfer of that commercial significance runs into MSAT capacity gaps, the consequences are not confined to the project schedule. Comparability data accumulates delays. Regulatory dossier timelines shift. The commercial implications of a six-month launch delay in a post-acquisition integration are material in ways that dwarf the cost of the talent gap that caused them.

The cascade is predictable: process deviations accumulate without experienced MSAT to diagnose and resolve them, tech transfer timelines extend, batch failures require investigation, and the regulatory narrative that supports the transfer becomes harder to maintain as exceptions multiply.

The most effective intervention is not always a permanent hire. In many transfer contexts, it is specifically not because the transfer itself is time-bounded, the expertise required is highly specialised, and the lead times for permanent recruitment make the hire impossible to complete before the window where it is needed.

What experienced MSAT contractors bring to a transfer is not just technical execution capacity. They bring the credibility that closes the transparency gap.

A contractor who has managed biologics transfers across multiple European sites, who has navigated the comparability requirements for a market authorisation in both EMA and national contexts, and who is known to the sending site's technical community, arrives with a reputation that changes the interpersonal dynamics of the transfer immediately. Questions are answered more fully. Process history is shared more candidly. The informal knowledge in the sending team's heads begins to move.

This matters most at the three points where transfers most commonly stall: the initial process characterisation review, where tacit knowledge is most consequential; the first manufacturing runs at the receiving site, where deviation management determines whether the transfer is tracking or in trouble; and the comparability assessment, where the regulatory narrative depends on having MSAT professionals who understand not just the data but the story it needs to tell.

Planning contractor involvement at these specific points not reactively, when a delay has already materialised, but in advance, as a deliberate component of the transfer strategy is what separates transfers that complete on schedule from those that enter the four-to-six-month delay zone.

If you are leading a tech transfer that involves a biologics, ADC, or peptide process; if the transfer crosses sites, organisations, or regulatory jurisdictions; and if your current team was sized for steady-state operations rather than a major transfer campaign the question worth asking now is not whether you have the headcount. It is whether the headcount you have carries the right transfer-specific experience to close the transparency gap with the sending team.

The regional talent market across the major European biopharma clusters is not going to become less competitive between now and your peak transfer window. CQV role demand in the Basel Corridor is up approximately 40% year-on-year. MSAT specialists in the Leiden cluster are typically already in role and effectively pre-allocated before formal searches begin. Dublin and Limerick technical operations postings are growing at 17% year-on-year.

In that environment, the four-to-six-month delay is not an outcome you discover when the transfer stalls. It is an outcome you build the conditions for, or avoid, in the planning decisions you make now.

The bottleneck in tech transfers is rarely the process. It is almost always the people and specifically, whether the right people are in place before the transfer needs them, not after it has already begun to slip.

Panda International supports MSAT, tech transfer, and technical operations hiring across the Netherlands, Belgium, Switzerland, and Ireland permanent and contract. For a confidential discussion about your transfer resource requirements, visit Panda International